

## ***numares* and Bruker sign agreement to enable advanced metabolomics-based clinical diagnostics**

BOSTON, USA/REGENSBURG, GERMANY – January 21, 2021: Leading metabolomics based diagnostics company ***numares AG*** and analytical instrumentation and solution provider **Bruker Corporation** have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs. The tests are based on the automated measurement of metabolites using a strong magnet field, and artificial intelligence. The platform is marketed under the *numares* brand **AXINON®**.

Based on a longstanding collaboration between the two companies, the agreement creates a combination of *numares*' expertise in leveraging metabolomics for software-based diagnostics with world-leading nuclear magnetic resonance (NMR) technology from Bruker. This leads to more rapid, accurate and personalized information about the severity and progress of diseases.

This collaboration will support the ongoing transition of **AXINON®** platform from research into routine clinical use, and makes it available to all patients as an affordable, day-to-day diagnostic standard. Two years ago, *numares* started a collaboration with US-based **Mayo Clinic** for joint diagnostic test development using metabolomics and NMR. The collaboration of *numares* and Bruker now marks a further milestone in the *numares* vision to bring these technologies into routine diagnostics.

The **AXINON®** platform based on NMR spectroscopy is a non-invasive technique that is uncovering new potential for the prevention and treatment of disease, including conditions in the kidney, heart, and liver, as well as cancer. The *numares* system measures various metabolic patterns and applies artificial intelligence (AI) to cluster and translate the results into clinical diagnosis. This rich source of information gives healthcare professionals new insight into disease management, and gives patients fast access to the right treatment. Likewise, the **AXINON®** platform also supports disease risk prediction, paving the way to new developments in precision medicine and companion diagnostics.

Dr. Volker Pfahlert, Director of the Board of *numares* says: "Our agreement will help to expand the exciting potential of NMR technology, long established in academic and clinical research, to the clinical diagnostics industry where *numares* already has a strong customer base. It paves the way for market entry of NMR diagnostics under FDA regulations, a prerequisite to make it accessible to all patients as day-to-day applications in routine clinical diagnostics. It


will support *numares* to better utilize its test development in several indications such as kidney disease, liver disease or neurological disorders.”

Dr. Iris Mangelschots, President of Bruker BioSpin’s Applied, Clinical and Industrial division comments: “The pandemic of 2020 has brought unimaginable challenges on a global scale. With the world’s spotlight sharply focused on the healthcare industry, our business has accelerated to develop the technology and diagnostic solutions that is desperately needed. The innovations born out of this demand have paved the way for future, highly advanced new product developments. Partnering with *numares* will bring our technology to the frontline healthcare industry, where it is most needed. NMR technology delivers the robust and reproducible results needed to support the advanced AI modelling techniques deployed by *numares*. Together, our complementary technologies offer a powerful arm in the fight against disease of the future.”

Co-CEO and President of *numares Group Corp.* Winton Gibbons concludes: “This agreement is a further important step in the commercialization of our products in the US. With *GFR<sub>NMR</sub>* we will soon launch a novel blood test to help identify and quantify impaired kidney function in patients with this more accurate, easy-to-access, and affordable diagnostic standard.”

Media:





## About numares

numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The *AXINON® System* employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. *Magnetic Group Signaling (MGS®)* is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at <https://www.numares.com/>

## For further information please contact:

numares  
Christiane Proll  
Tel.: +49 941 280 949-14  
E-Mail: [christiane.proll@numares.com](mailto:christiane.proll@numares.com)